

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**


IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 1

1 2 3 4 5 6 7 8



β -actin

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 2

1 2 3 4 5



IL-10

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 3





FIGURE 4



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 5A

1 2 3 4 5






FIGURE 5B

1 2 3 4 5



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 6



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 7

		Leader -----	
RAT	ATGGGCAGTCCGGTATT	CAGGAGACCTTTCTGCCATCTGTCCACCTACAGCCTGCTCTGGGCCATAG	67
MOU	-----T-----	-----C-----A-T-----G-----	67
HUM	-----GA-----TG-----C-----CT-----T-----G-T-----T-----G-----		55
		V-like domain -----	
RAT	CAGCAGTAGCGCTGAGCACAGCTCAAGTGGGAAGTGGTGACCCAGGATGAAAGAAAGCTGCTGCACAC		134
MOU	-----	-----GC-----	134
HUM	-----G-T-----T-----A-----C-----A-----T-----		122
RAT	AACTGCATCCTTACGCTGTTCTCTAAAAACAACCCAGGAACCCTTGATTGTGACATGGCAGAAAAAG		201
MOU	-----A-----T-----		201
HUM	-----T-----AAA-C-----GC-----ATG-----G-C-C-----		189
RAT	AAAGCCGTAGGCCCAGAAAAATGGTCACTTACAGCAAAGCCCATGGGGTTGTCTTCAGCCCACT		268
MOU	-----GA-----C-----A-----A-C-----TG-----		268
HUM	-----T-A-----C-T-----G-GAA-----G-G-C-----TG-----		256
RAT	ACAAAGACAGGATAAACATCACTGAGCTGGGACTCTTGAACACAAGCATCACCTTCTGGAACACAAC		335
MOU	-----TG-----A-----G-----T-----CA-----		335
HUM	-T-G-----A-----T-CC-----C-A-----T-C-----T-TC--		323
RAT	CCTGGATGATGAGGGTTGCTACATGTGTCTCTTCAACATGTTTGGATCTGGGAAGGTCTCTGGGACA		402
MOU	-A-T-GA-----GA-C-----C-----T-----CA-----A-A-----		402
HUM	-----G-----A-G-T-----T-CC-----T-T-----A-A-G-----		390
		C-like domain -----	
RAT	GCTTGCCTTACTCTCTATGTACAGCCCATAGTACACCTTCACTACAACCTATTTGAAGACCACCTAA		469
MOU	-----C-----		469
HUM	--C-----C-CG-----TC-----A-TC-C-----		457
RAT	ACATCACGTGCTCTGCAACTGCCCGCCCAGCCCCTGCCATCTCCTGGAAGGGCACTGGGTCCAGGAAT		536
MOU	-----T-----G-----T-----A-----T-----A-----		536
HUM	-T-----T-----C-----CATGG--T-----T-C-C-----		524
RAT	TGAGAATAGTACTGAGAGTCACTCCCATTCAAATGGGACTACATCTGTCCAGCATCCTCCGGGTC		603
MOU	-----C-----T-----		603
HUM	---A-----A-T-C-TG-T-CC-----C-G-----T-----ATA--		591
RAT	AAAGACCCCCAAACTCAGGTTGGAAAGGAAGTGATCTGCCAGGTTTTATACTTGGGGAATGTGATTG		670
MOU	-----		670
HUM	-----T-G-A-----G-G-----GC-GC-C-----C-----CC--		658
		Transmembrane region -----	
RAT	ACTACAAGCAGAGTCTGGACAAAGGATTTTGGTTTTTCAGTCCCCTGCTGCTGAGCATTGTTTCTCT		737
MOU	-----T-----T-----A-----		737
HUM	---TT-----A-CCG-CA-----C-A-----T-G-AT-----A-----C--		725
		Cytoplasmic region -----	
RAT	GGTAATTCTTCTGGTCTTGATCTCCATCTTATTATACTGGAAACGGCACCGAAATCAGGAGCGGGGT		804
MOU	-----A-----C-----T-----		804
HUM	-----C-C-A-----A-----C-G-----T-----G-----C-A-----		792
RAT	GAGTCATCACAGGGGATGCAAAGAATGAAATAA		837
MOU	--A-----		837
HUM	---TG-----AG-T-----A-----C-----		825

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 8

Leader sequence—————

-30 -1

RAT M G S P V F R R P F C H L S T Y S L L W A I A A V A L S T A

MOU -----L-----I---G-----

HUM - I - M - - - S - - - - V - - V M - - - - V - - C - - -

|V-like domain (domain I) ————— *

RAT Q V E V V T Q D E R K L L H T T A S L R C S L K T T Q E P L

MOU -----A-----S-----

HUM ---Q-----E---Y-----K-----QNA---A---

31 **

RAT I V T W Q K K K A V G P E N M V T Y S K A H G V V I Q P T Y

MOU -----S-----T-----A---

HUM -----E N-----

61 ** ** *

RAT K D R I N I T E L G L L N T S I T F W N T T L D D G G C Y M

MOU -----V-----W--S-----H I G-----

HUM ---K-----Q-----T-----I-----E-----

91* ** |C-like domain (domain II) —————

RAT C L F N M F G S G K V S G T A C L T L Y V Q P I V H L H Y N

MOU -----T-----Q-----

HUM -----F G--I-----V-----S-----K

121 ** *

RAT Y F E H H L N I T C S A T A R P A P A I S W K G T G S G I E

MOU -----T-----T-----

HUM F S-----M V F-----V P R-----

151**

RAT N S T E S H S H S N G T T S V T S I L R V K D P K T Q V G K

MOU -----F-----

HUM -----V T L S--P-----H I-----N-----

181 * |Transmembrane region —————

RAT E V I C Q V L Y L G N V I D Y K Q S L D K G F W F S V P L L

MOU -----

HUM -----H---T--T--F---T V N---Y-----

211 |Cytoplasmic region —————

RAT L S I V S L V I L L V L I S I L L Y W K R H R N Q E R G E S

MOU -----I-----

HUM -----V-----D-----L

241

RAT S Q G M Q R M K

MOU -----

HUM -----V--K---T

* invariant cysteine residues: ** invariant asparagine (N-linked oligosaccharides)

FIGURE 9A






FIGURE 9B



CELLS added to C57BL/6 RESPONDER SPLEEN CELLS

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 11



NPC from Flt3 treated mice

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 12






FIGURE 13



CELLS added to C3H RESPONDER SPLEEN CELLS

FIGURE 14



NPC cells infused into renal transplant recipients

FIGURE 15





FIGURE 16



Monoclonal antibodies added to culture

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 17A





FIGURE 17B



Monoclonal antibodies added to culture

- IL-2 (pg/ml)
- IFN- γ (ng/ml)
- ▨ IL-4 (pg/ml)
- ▩ IL-10 (ng/ml)

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 18A




FIGURE 18B






FIGURE 19A



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 19B







FIGURE 20

FIGURE 21A



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 21B






FIGURE 22A



- BL/6 with BL/6
- BL/6 with C3H:IgG
- BL/6 with C3H:CD200Fc
- ▲- Normal C3H+IgG
- △- Normal C3H:CD200Fc

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 22B



CD200Fc reverses protection from early mortality in C57BL/6 mice immunized with CD80-transfected EL4 cells






FIGURE 23

FIGURE 24A




APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 24B



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

Relative CD200 mRNA expression in spleen following immunization with EL4-CD86 vs EL4-CD80



Cells used for immunization of C57BL/6

FIGURE 25

FIGURE 26A




FIGURE 26B





FIGURE 27B



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 29A




FIGURE 29B




FIGURE 30A




FIGURE 30B




FIGURE 31A




FIGURE 31B

